Meeting Report: American Urological Association (AUA)

Published:

AUA’s 2018 annual meeting was held May 18-21 in San Francisco. Twelve scientific abstracts featured focused ultrasound technology, each around the theme of predicting or measuring outcomes after treatment. One significant highlight was Profound Medical’s presentation of initial data from their TULSA-PRO Ablation Clinical Trial.

AUA2018The full text for each abstract can be found online in the Journal of Urology, Volume 199 Issue 4 (Supplement).

SALVAGE HIGH-INTENSITY FOCUSED ULTRASOUND FOR LOCALLY RECURRENT PROSTATE CANCER AFTER LOW-DOSE-RATE BRACHYTHERAPY: ONCOLOGIC AND FUNCTIONAL OUTCOMES.
Thomas Hostiou, Albert Gelet, Jean Yves Chapelon, Olivier Rouvière, Florence Mege Lechevalier, Helene Tonoli-Catez, Pascal Pommier, Lionel Badet, and others. J Urol 199;4: e1079.
Abstract ID: LBA22

SALVAGE PROSTATECTOMY AFTER FOCAL THERAPY – SINGLE CENTRE EXPERIENCE
Jaime Herrera-Caceres, Dixon T.S. Woon, Hanan Goldberg, Thenappan Chandrasekar, Zachary Klaassen, Neil Fleshner. J Urol 199;4:e49.
Abstract ID: MP05-16

ONCOLOGICAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY IN A CONTEMPORARY, MULTICENTRE SERIES OF 395 CASES
Paolo Gontero, Giancarlo Marra, Paolo Alessio, Marco Oderda, Anna Palazzetti, Francesca Pisano, Antonino Battaglia, Stefania Munegato, and others. J Urol 199;4:e128–e129.
Abstract ID: MP11-05

RECURRENCE RATES FOLLOWING TESTOSTERONE THERAPY IN A LARGE CLINICAL COHORT OF MEN WITH PROSTATE CANCER
Abraham Morgentaler, Dean Magauran, Dylan Neel, Yonah Krakowsky, William Conners. J Urol 199;4:e206.
Abstract ID: MP17-03

HIFU DOSE ESCALATION LEADS TO FEWER RECURRENCES IN FOLLOWING FOCAL HIFU IN PROSTATE CANCER.
Philipp M. Huber, Naveed Afzal, Manit Arya, Silvan Boxler, Susan Charman, Andrew Cornaby, Tim Dudderidge, Mark Emberton, and others. J Urol 199;4:e378. This abstract was noted on Urotoday.com.
Abstract ID: MP30-10

PREDICTORS OF POOR FUNCTIONAL OUTCOMES AFTER FOCAL HIGH INTENSITY FOCUSSED ULTRASOUND (HIFU).
Taimur T Shah, Max Peters, Stephanie Guillaumier, Manit Arya, Naveed Afzal, Feargus Hosking-Jervis, Tim Dudderidge, Richard Hindley, and others. J Urol 199;4:e378–e379. This abstract was noted UroToday.com. 
Abstract ID: MP30-11

COMPREHENSIVE EVALUATION OF COMPLICATIONS OF FOCAL THERAPY: A STANDARDIZED METHODOLOGY.
Arnas Bakavicius, Rafael Sanchez-Salas, Paolo Dell’Oglio, Silvia Garcia-Barreras, Adalberto Castro-Alfaro, Francois Rozet, Alexandre Ingels, Eric Barret, and others. J Urol 199;4:e657–e658.
Abstract ID: PD34-06

PSA FAILS TO PREDICT TREATMENT FAILURE IN FOCAL HIGH-INTENSITY FOCUSED ULTRASOUND THERAPY IN PROSTATE CANCER.
Philipp M. Huber, Naveed Afzal, Manit Arya, Silvan Boxler, Susan Charman, Andrew Cornaby, Tim Dudderidge, Mark Emberton, and others. J Urol 199; 4:e658.
Abstract ID: PD34-07

DETERMINANTS OF ERECTILE DYSFUNCTION FOLLOWING FOCAL ABLATIVE THERAPY FOR LOCALISED PROSTATE CANCER.
Eoin Dinneen, Neil McCartan, Hashim U. Ahmed, Mark Emberton, Richard Hindley, Clare Allen, Louise Dickinson, Suks Minhas, and others. J Urol 199;4: e658–e659.
Abstract ID: PD34-08

MISINFORMATION ON THE INTERNET REGARDING ABLATIVE THERAPIES FOR PROSTATE CANCER.
Denise Asafu-Adjei, Nina Mikkilineni, Elisabeth Sebesta, Elias S. Hyams. J Urol 199;4:e660.
Abstract ID: PD34-11

DEVELOPMENT OF A NATIONALLY-REPRESENTATIVE FOCAL THERAPY MEDICAL DEVICE REGISTRY.
Ron Golan, Adrien Bernstein, Art Sedrakyan, Timothy McClure, Jim Hu. J Urol 199;4:e660.
Abstract ID: PD34-12

OUTCOMES OF SALVAGE ROBOT-ASSISTED RADICAL PROSTATECTOMY POST PRIMARY RADIATION AND THERMAL ABLATION THERAPIES.
Mario Mekhail, Luis Medina, Giovanni Cacciamani, Akbar Ashrafi, Matthew Winter, Peter Mekhail, Sameer Chopra, Andre Berger, and others. J Urol 199;4:e815.
Abstract ID: PD42-04